Halozyme to Participate in the 8th Annual Evercore Healthcare Conference
Halozyme (NASDAQ: HALO) announced that Dr. Helen Torley, president and chief executive officer, will present and host investor meetings at the 8th Annual Evercore Healthcare Conference.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Halozyme (NASDAQ: HALO) announced that Dr. Helen Torley, president and chief executive officer, will present and host investor meetings at the 8th Annual Evercore Healthcare Conference. The presentation is scheduled for Tuesday, December 2, 2025 at 10:20 AM PT / 1:20 PM ET. A live audio webcast will be available on the company's Investor Relations website, and replays will be accessible for 90 days after the conference.
Details
News Market Reaction – HALO
On Nov 25, the day this news came out, HALO closed 1.59% below the previous close.
Data tracked by StockTitan Argus for the Nov 25 session.
AI-generated analysis. How Rhea-AI works. Not financial advice.
The presentation is scheduled for Tuesday, December 2 at 10:20am PT / 1:20pm ET.
A live audio webcast will be available on the Investor Relations section of the Company's website. Replays of the audio webcasts will be available for 90 days following the conference.
About Halozyme
Halozyme is a biopharmaceutical company advancing disruptive solutions to improve patient experiences and outcomes for emerging and established therapies.
As the innovators of ENHANZE® drug delivery technology with the proprietary enzyme rHuPH20, Halozyme's commercially validated solution facilitates the subcutaneous delivery of injected drugs and fluids, reducing treatment burden and improving convenience. ENHANZE® has touched more than one million patient lives through ten commercialized products across over 100 global markets and is licensed to leading pharmaceutical and biotechnology companies including Roche, Takeda, Pfizer, Janssen, AbbVie, Eli Lilly, Bristol-Myers Squibb, argenx, ViiV Healthcare, Chugai Pharmaceutical, Acumen Pharmaceuticals, and Merus N.V.
Halozyme is also developing Hypercon™ to expand the breadth of its drug delivery technology portfolio. Hypercon™ is an innovative microparticle technology that is expected to set a new standard in hyper concentration of drugs and biologics that can reduce the injection volume for the same dosage and expands opportunities for at-home and health care provider administration. The addition of Hypercon™ enhances our ability to transform the patient treatment experience by enabling the creation and delivery of highly concentrated biologics, substantially broadening the scope of therapeutics that can be delivered subcutaneously. The Hypercon™ technology has been licensed to leading biopharmaceutical partners, including Johnson & Johnson, Eli Lilly, and argenx.
Halozyme also develops, manufactures, and commercializes drug-device combination products using advanced auto-injector technologies designed to improve convenience, reliability, and tolerability, enhancing patient comfort and adherence. The Company has two proprietary commercial products, Hylenex® and XYOSTED®, partnered commercial products, and ongoing development programs with Teva Pharmaceuticals and McDermott Laboratories Limited, an affiliate of Viatris Inc.
Halozyme is headquartered in
For more information, visit www.halozyme.com and connect with us on LinkedIn and Twitter.
Contact:
Tram Bui
VP, Investor Relations and Corporate Communications
609-333-7668
tbui@halozyme.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/halozyme-to-participate-in-the-8th-annual-evercore-healthcare-conference-302625341.html
SOURCE Halozyme Therapeutics, Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.